What's in YUAN Wei-jie's pipeline?

YUAN Wei-jie has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with YUAN Wei-jie's portfolio?

Top competitors by shared drug class: University Hospital Muenster.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/yuan-wei-jie.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

YUAN Wei-jie — Portfolio Competitive Intelligence Brief

YUAN Wei-jie pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
keto-amino acids	keto-amino acids	marketed	Amino acid supplement / Nutritional therapeutic		Nephrology, Hepatology, Metabolic disorders

Therapeutic area mix

Nephrology, Hepatology, Metabolic disorders · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University Hospital Muenster · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for YUAN Wei-jie:

Cite this brief

Drug Landscape (2026). YUAN Wei-jie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yuan-wei-jie. Accessed 2026-05-16.